UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

Benzinga · 1d ago
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.